Trials / Completed
CompletedNCT01518374
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,768 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Florbetapir F 18 | 370 MBq (10 mCi) |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2017-05-03
- Completion
- 2017-05-03
- First posted
- 2012-01-26
- Last updated
- 2018-07-18
- Results posted
- 2018-06-14
Locations
26 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01518374. Inclusion in this directory is not an endorsement.